tldrdailynews.com logo
Tag

Weight Loss Drugs

All articles tagged with #weight loss drugs

GLP-1 Weight-Loss Drugs: Common Side Effects and Management Tips
health5 days ago

GLP-1 Weight-Loss Drugs: Common Side Effects and Management Tips

GLP-1 medications like Ozempic, Wegovy, and Zepbound can aid weight loss but commonly cause side effects ranging from GI symptoms (nausea, vomiting, constipation/diarrhea) to dehydration, pancreatitis, gallstones, gastroparesis, and dental issues. Doctors advise staying hydrated, prioritizing protein, maintaining strength training, and timing meals (avoid eating 3–4 hours before bed), while reporting persistent or severe symptoms. Long-term risks are still unknown, so these drugs should be used under medical guidance for those who meet criteria.

via HuffPost|
#diabetes#gastrointestinal#glp-1
GLP-1 injections reshape the UK's obesity fight
health13 days ago

GLP-1 injections reshape the UK's obesity fight

GLP-1 weight‑loss injections, notably Wegovy and Mounjaro, are transforming obesity treatment in the UK and globally, delivering significant weight loss in trials and real life, but NHS access remains tightly restricted by cost under NICE criteria, prompting concerns about inequality and a growing private market; with more than 50 obesity drugs in trials and new forms like tablets on the horizon, experts expect broader options that could reduce surgery needs while underscoring the importance of addressing underlying causes.

via BBC|
#glp-1#health#nhs
Wegovy-Fueled Q1 Beat Lifts Novo Nordisk's 2026 Outlook
business23 days ago

Wegovy-Fueled Q1 Beat Lifts Novo Nordisk's 2026 Outlook

Novo Nordisk beat Q1 estimates on strong Wegovy demand, posting $15.17 billion in revenue and $1.04 in adjusted EPS, and raised its 2026 outlook. The Wegovy pill launch contributed to early sales, with prescriptions surpassing 2 million since launch and more than $2.2 billion in first‑quarter Wegovy pill sales. Management now expects adjusted sales and operating profit to fall 4%–12% for the year, easing fears of a sharp slowdown in the obesity drug market, and the stock moved higher on the report.

via TipRanks|
#business#earnings#novo-nordisk
GLP-1 Weight-Loss Boom Sparks Hair-Care Market Push
business27 days ago

GLP-1 Weight-Loss Boom Sparks Hair-Care Market Push

As GLP-1 weight-loss drugs grow popular, some users experience temporary hair shedding, prompting a new wave of at-home hair-care products and scalp treatments. The trend is rising quickly: roughly 13% of U.S. adults use GLP-1 meds, with projections of 25 million on them by 2030, and Circana finds GLP-1 households spend more on beauty. Brands from Ulta to Redken, Nutrafol, and KeraFactor are expanding targeted offerings, while doctors note hair recovery varies and depends on nutrition and time, suggesting consumer loyalty as results take months to appear.

via CNBC|
#beauty-industry#business#circana
Lilly rides weight-loss drug wave to first-quarter profit surge
business29 days ago

Lilly rides weight-loss drug wave to first-quarter profit surge

Eli Lilly more than doubled its Q1 profits as demand for obesity and diabetes medications drove revenue higher, with Mounjaro sales at $8.7bn and Zepbound at $4.2bn (up 80%), prompting a raised outlook. Foundayo was approved and launched this month but isn’t included in the quarter’s figures. Shares rose about 9%, and Lilly faces competitive pressure from Novo Nordisk while Medicare deals helped push Zepbound prices down even as volumes grew; investors will watch for weekly prescription data and updates on Foundayo’s performance.

via Financial Times|
#business#eli-lilly#foundayo
Medicare pauses BALANCE GLP-1 pilot as transitional coverage extends through 2027
health1 month ago

Medicare pauses BALANCE GLP-1 pilot as transitional coverage extends through 2027

The Trump administration indefinitely delays the BALANCE pilot that would have let private Medicare drug plans cover GLP-1 weight-loss medicines, after insurers voiced concerns, while a transitional program will cover the drugs through 2027 with Medicare bearing the cost and no requirement for plans to take on financial risk. This means $50 co-pays won’t count toward deductibles or out-of-pocket max for the time being. The Medicaid portion of the initiative continues, with states able to apply by July 31, and analysts see the move as buying time to reassess BALANCE while keeping access available for beneficiaries.

via Axios|
#balance#glp-1#health
One Medical rolls out nationwide GLP-1 weight-loss program integrated with primary care
healthcare1 month ago

One Medical rolls out nationwide GLP-1 weight-loss program integrated with primary care

Amazon's One Medical is launching a nationwide GLP-1 weight-loss program that combines prescriptions with ongoing primary care, including virtual and in-person visits, lab monitoring, and integrated care through Amazon Pharmacy. The initiative, which offers pricing options and aims to improve long-term outcomes, comes as competitors push similar GLP-1 platforms and underscores ongoing gaps in obesity care when care isn’t closely managed.

via Axios|
#amazon-pharmacy#glp-1#healthcare
Secret GLP-1 Weight-Loss: Why Some Women Hide Medication From Partners
health1 month ago

Secret GLP-1 Weight-Loss: Why Some Women Hide Medication From Partners

Some women using GLP-1 weight-loss meds like Wegovy keep their use secret from partners to avoid lectures and stigma, a pattern highlighted by personal stories and a Reddit thread. Telemedicine can make obtaining prescriptions easier, but hiding meds can complicate medical care and complicate conversations about health goals. Experts suggest planning conversations with partners and being honest about motivations, while recognizing the broader issues of weight stigma and autonomy in treatment.

via SELF Magazine|
#glp-1#health#relationships
health-and-medicine1 month ago

AI analysis flags overlooked side effects of GLP-1 weight-loss drugs, including menstrual changes

A Penn study used AI to scan more than 400,000 Reddit posts and found that a significant portion of users taking GLP-1 receptor agonists (like semaglutide and tirzepatide) reported side effects—most commonly nausea, fatigue, and GI issues—with about 4% mentioning menstrual changes. The researchers caution that these reports do not prove causation and emphasize broader data collection beyond Reddit to better capture potential adverse effects and inform labeling.

via Ground News|
#ai-analysis#glp-1#health-and-medicine
Cost pressures push states to roll back Medicaid coverage for GLP-1 obesity drugs
health1 month ago

Cost pressures push states to roll back Medicaid coverage for GLP-1 obesity drugs

With GLP-1 obesity drugs becoming costlier, several states and major cities are restricting or ending Medicaid or public-employee coverage for weight‑loss uses, arguing short-term budget relief even as critics warn this could worsen health outcomes. Costs surged from about $13.7B in 2018 to $71.7B in 2023, leading to coverage changes in California, New Hampshire, Pennsylvania, and South Carolina (with Michigan tightening criteria) and proposals in Rhode Island, New York City, and Boston.

via The Guardian|
#glp-1#health#medicaid
Two Gene Variants Linked to Different Weight-Loss Responses on Obesity Drugs
health1 month ago

Two Gene Variants Linked to Different Weight-Loss Responses on Obesity Drugs

A Nature study of about 15,000 people using obesity drugs (Wegovy and Mounjaro) finds that certain genetic variants influence weight loss. One variant, especially in two copies, is associated with more weight loss; another variant may raise the risk of nausea. On average, participants lost 11.7% of body weight over eight months, with some achieving as much as 30%. Differences by sex, age, and ancestry, plus drug type, dose, duration and lifestyle, also shape outcomes. While promising for tailoring treatment, these findings are early and not yet practice-changing; further trials are needed to guide precision medicine in obesity care.

via BBC|
#genetics#health#obesity
Genes Partly Predict Response to GLP-1 Weight-Loss Shots
science1 month ago

Genes Partly Predict Response to GLP-1 Weight-Loss Shots

Scientists analyzed data from 27,885 patients taking GLP-1 obesity drugs and found two gut-hormone gene variants may partly explain why weight loss and side-effects vary: rs10305420 is linked to slightly more weight loss, while rs1800437 is linked to nausea with tirzepatide. But the genetic contribution is modest; non-genetic factors like sex, drug type, dose, and duration explain much more of the variability, so genetics are not yet ready to guide routine treatment, though the findings could inform future precision approaches.

via The Guardian|
#genetics#glp1#obesity